Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $98.1 million.

  • Niagen Bioscience's Liabilities and Shareholders Equity rose 7362.97% to $98.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.3 million, marking a year-over-year increase of 5449.86%. This contributed to the annual value of $68.3 million for FY2024, which is 2422.31% up from last year.
  • Latest data reveals that Niagen Bioscience reported Liabilities and Shareholders Equity of $98.1 million as of Q3 2025, which was up 7362.97% from $91.5 million recorded in Q2 2025.
  • Niagen Bioscience's Liabilities and Shareholders Equity's 5-year high stood at $98.1 million during Q3 2025, with a 5-year trough of $45.7 million in Q3 2022.
  • Over the past 5 years, Niagen Bioscience's median Liabilities and Shareholders Equity value was $54.5 million (recorded in 2023), while the average stood at $61.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 2920.48% in 2022, then soared by 7362.97% in 2025.
  • Over the past 5 years, Niagen Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $57.8 million in 2021, then dropped by 6.54% to $54.1 million in 2022, then rose by 1.68% to $55.0 million in 2023, then increased by 24.22% to $68.3 million in 2024, then skyrocketed by 43.73% to $98.1 million in 2025.
  • Its last three reported values are $98.1 million in Q3 2025, $91.5 million for Q2 2025, and $81.3 million during Q1 2025.